{"hands_on_practices": [{"introduction": "A crucial skill for any immunologist is the ability to interpret experimental data to identify underlying biological processes. Immunogenic cell death (ICD) is not defined by a single marker, but by a characteristic spatiotemporal sequence of molecular events. This exercise challenges you to apply your knowledge of this canonical sequence to interpret a realistic, time-resolved dataset, distinguishing the signature of ICD from other forms of cell death like primary necrosis [@problem_id:2858331].", "problem": "A research team treats cultured human carcinoma cells with a chemotherapeutic agent reported to induce immunogenic cell death (ICD). They acquire flow cytometry readouts at multiple time points from matched replicates. Mean fluorescence intensity (MFI) of surface-exposed calreticulin (ecto-CRT) increases by approximately 2-fold relative to vehicle at 4 h. High Mobility Group Box 1 (HMGB1) in the extracellular compartment, quantified by a bead-based flow immunoassay on culture supernatants, shows no change at 4 h but rises markedly at 16 h. Using the canonical, spatiotemporally ordered emission of damage-associated molecular patterns (DAMPs) that defines immunogenic cell death, and contrasting it with primary necrotic leakage, which interpretation is most consistent with these data?\n\nA. The observed kinetics are consistent with canonical immunogenic cell death, in which pre-apoptotic ecto-calreticulin exposure precedes late HMGB1 release; primary necrosis would typically exhibit early HMGB1 leakage concurrent with membrane rupture.\n\nB. The data argue against immunogenic cell death because HMGB1 must be released before calreticulin exposure to prime dendritic cells.\n\nC. The pattern indicates primary necrosis, since HMGB1 elevation at 16 h is diagnostic of membrane rupture as the initiating event.\n\nD. The findings are best explained by non-immunogenic apoptosis, as calreticulin exposure alone is a hallmark of tolerogenic apoptosis and HMGB1 appearance is unrelated.", "solution": "The problem statement must first be subjected to rigorous validation.\n\n**Step 1: Extract Givens**\n- **System:** Cultured human carcinoma cells.\n- **Treatment:** A chemotherapeutic agent reported to induce immunogenic cell death (ICD).\n- **Control:** Vehicle-treated matched replicates.\n- **Data Point 1:** Mean fluorescence intensity (MFI) of surface-exposed calreticulin (ecto-CRT) increases by approximately 2-fold relative to vehicle at 4 hours.\n- **Data Point 2:** High Mobility Group Box 1 (HMGB1) in the extracellular compartment shows no change at 4 hours but rises markedly at 16 hours.\n- **Core Question:** Interpret these data in the context of the canonical, spatiotemporally ordered emission of damage-associated molecular patterns (DAMPs) that defines immunogenic cell death, contrasted with primary necrotic leakage.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded. Immunogenic cell death is a well-defined form of regulated cell death in immunology and oncology. The DAMPs mentioned—calreticulin (CRT) and High Mobility Group Box 1 (HMGB1)—are central to this process. The experimental techniques (flow cytometry, bead-based immunoassay) and the observed time points (4 h, 16 h) are standard in the field of cell biology. The core of the problem rests on the established spatiotemporal hierarchy of DAMP emission during ICD, which is a known and testable scientific concept. The problem is well-posed, objective, self-contained, and devoid of scientific or logical flaws. It asks for a reasoned interpretation based on provided data and established biological principles.\n\n**Step 3: Verdict and Action**\nThe problem statement is valid. A solution will be derived.\n\n**Derivation**\n\nImmunogenic cell death (ICD) is a regulated process that elicits an adaptive immune response. Its defining characteristic is the emission of DAMPs in a specific spatiotemporal sequence. This sequence distinguishes ICD from non-immunogenic apoptosis and from primary necrosis.\n\nThe canonical sequence of key DAMPs in ICD is as follows:\n1.  **Pre-apoptotic Surface Exposure of Calreticulin (ecto-CRT):** Undergoing endoplasmic reticulum (ER) stress, the cell translocates CRT from the ER lumen to the cell surface. This is an early event, occurring before the loss of plasma membrane integrity. Ecto-CRT serves as a potent \"eat-me\" signal, promoting the engulfment of the dying cell by antigen-presenting cells, particularly dendritic cells (DCs).\n2.  **Late Release of High Mobility Group Box 1 (HMGB1):** HMGB1 is a nuclear protein. Its release into the extracellular milieu requires the loss of plasma membrane integrity. In the context of ICD, which is a form of apoptosis, this loss of integrity occurs during the late stages, a phase known as secondary necrosis. Therefore, HMGB1 release is a late event, occurring hours after the initial apoptotic signals such as ecto-CRT exposure. Once released, HMGB1 binds to Toll-like receptor 4 (TLR4) on DCs, promoting their maturation and antigen presentation capabilities.\n\nIn contrast, **primary necrosis** is a non-regulated form of cell death caused by acute injury, leading to a rapid and catastrophic rupture of the plasma membrane. In this scenario, intracellular contents, including cytosolic proteins and nuclear proteins like HMGB1, are released passively and immediately into the extracellular space.\n\nLet us apply these principles to the provided data:\n-   An increase in ecto-CRT is observed at 4 hours. This aligns perfectly with the description of an early, pre-apoptotic event in the ICD cascade.\n-   HMGB1 levels in the supernatant are unchanged at 4 hours but rise markedly at 16 hours. The absence of HMGB1 at the early time point indicates that the plasma membrane is still largely intact. The significant release at the late time point (16 h) is consistent with its passive release during secondary necrosis, which follows the initial apoptotic program.\n\nThe observed sequence—early ecto-CRT exposure followed by late HMGB1 release—is the canonical signature of immunogenic cell death. It is fundamentally inconsistent with primary necrosis, which would manifest as an early, simultaneous release of intracellular components, including HMGB1, at the time of membrane rupture.\n\n**Evaluation of Options**\n\n**A. The observed kinetics are consistent with canonical immunogenic cell death, in which pre-apoptotic ecto-calreticulin exposure precedes late HMGB1 release; primary necrosis would typically exhibit early HMGB1 leakage concurrent with membrane rupture.**\nThis statement accurately describes the spatiotemporal DAMP signature of canonical ICD (early ecto-CRT, late HMGB1). It correctly contrasts this with primary necrosis, where HMGB1 release would be an early event. The experimental data fit this model precisely.\n**Verdict: Correct.**\n\n**B. The data argue against immunogenic cell death because HMGB1 must be released before calreticulin exposure to prime dendritic cells.**\nThis statement is factually incorrect. The canonical sequence of DAMP signaling in ICD involves early ecto-CRT exposure as an \"eat-me\" signal, followed by late HMGB1 release as a maturation signal for DCs that have phagocytosed the dying cells. Reversing this order contradicts the established mechanism of ICD.\n**Verdict: Incorrect.**\n\n**C. The pattern indicates primary necrosis, since HMGB1 elevation at 16 h is diagnostic of membrane rupture as the initiating event.**\nThis interpretation is flawed. While HMGB1 release is indeed a marker of membrane rupture, its appearance at a late time point (16 h), long after an early apoptotic signal (ecto-CRT at 4 h), indicates that membrane rupture is a *consequence* of apoptosis (i.e., secondary necrosis), not the *initiating* event. In primary necrosis, membrane rupture is the initiator, and HMGB1 release would be observed much earlier.\n**Verdict: Incorrect.**\n\n**D. The findings are best explained by non-immunogenic apoptosis, as calreticulin exposure alone is a hallmark of tolerogenic apoptosis and HMGB1 appearance is unrelated.**\nThis statement is incorrect on two counts. First, ecto-CRT is a quintessential \"eat-me\" signal that defines *immunogenic* cell death, not tolerogenic (silent) apoptosis. Second, to dismiss the coordinated appearance of HMGB1 as \"unrelated\" is to ignore a critical piece of data. A valid interpretation must account for all observations. The combination of early ecto-CRT and late HMGB1 is the specific signature of ICD.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "2858331"}, {"introduction": "The release of damage-associated molecular patterns (DAMPs) is central to ICD, but how do these molecules trigger an immune response? The answer lies in the fundamental principles of receptor-ligand binding. This practice explores the interaction between the DAMP adenosine triphosphate (ATP) and its receptor P2RX7, a key step in inflammasome activation. By deriving and applying the standard receptor occupancy formula, you will quantify how localized high concentrations of a DAMP can drive a potent biological signal [@problem_id:2858396].", "problem": "In immunogenic cell death, dying tumor cells release adenosine triphosphate (ATP) as a danger-associated molecular pattern (DAMP) that engages the purinergic receptor P2X ligand-gated ion channel 7 (P2RX7) on myeloid cells to promote NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome activation and interleukin-1β (IL-1β) maturation. Consider a population of P2RX7 receptors on the surface of a macrophage exposed to extracellular ATP microdomains produced by a local necrotic focus. Assume that receptor occupancy follows reversible mass-action binding of ligand $L$ to receptor $R$, with equilibrium dissociation constant $K_{d}$ defined by $K_{d} = \\frac{[L][R]}{[RL]}$, where $[RL]$ is the concentration of ligand-bound receptor and $[R]$ is free receptor. Let the total receptor concentration be $[R]_{T} = [R] + [RL]$, and define the fractional occupancy as $f = \\frac{[RL]}{[R]_{T}}$. \n\nYou are given that the ATP affinity for P2RX7 is $K_{d} = 100\\,\\mu\\text{M}$. Two extracellular ATP microdomains are measured: a diffuse field with $[\\text{ATP}] = 10\\,\\mu\\text{M}$ and a peri-necrotic microdomain with $[\\text{ATP}] = 1\\,\\text{mM}$. \n\nUsing only the definition of $K_{d}$ and the conservation of receptor, first derive a general expression for $f$ in terms of $[L]$ and $K_{d}$. Then evaluate the receptor fractional occupancy at $[\\text{ATP}] = 10\\,\\mu\\text{M}$ and $[\\text{ATP}] = 1\\,\\text{mM}$. Assuming, for short exposures, that the likelihood of NLRP3 inflammasome activation scales proportionally with P2RX7 occupancy, qualitatively state which microdomain is more likely to trigger activation. Finally, report the fold-change in receptor occupancy (the ratio of occupancy at $1\\,\\text{mM}$ ATP to that at $10\\,\\mu\\text{M}$ ATP). \n\nExpress the final fold-change as a pure number without units and round your final answer to three significant figures.", "solution": "The problem as stated is subjected to validation.\n\nStep 1: Extraction of Givens.\n- The binding of ligand $L$ to receptor $R$ is reversible and follows mass-action kinetics.\n- Equilibrium dissociation constant is defined as $K_{d} = \\frac{[L][R]}{[RL]}$.\n- Total receptor concentration is defined as $[R]_{T} = [R] + [RL]$, where $[R]$ is the concentration of free receptor and $[RL]$ is the concentration of ligand-bound receptor.\n- Fractional occupancy is defined as $f = \\frac{[RL]}{[R]_{T}}$.\n- The affinity of adenosine triphosphate (ATP) for the P2RX7 receptor is given by its dissociation constant, $K_{d} = 100\\,\\mu\\text{M}$.\n- Two ligand concentrations are provided: a diffuse field with $[L]_{1} = [\\text{ATP}] = 10\\,\\mu\\text{M}$ and a peri-necrotic microdomain with $[L]_{2} = [\\text{ATP}] = 1\\,\\text{mM}$.\n- An assumption is made that the likelihood of NLRP3 inflammasome activation is proportional to the fractional occupancy, $f$.\n- The tasks are to: 1. Derive an expression for $f$ in terms of $[L]$ and $K_{d}$. 2. Evaluate $f$ for both given ATP concentrations. 3. Qualitatively compare the likelihood of activation for the two concentrations. 4. Calculate the fold-change in occupancy, defined as the ratio of occupancy at $1\\,\\text{mM}$ to that at $10\\,\\mu\\text{M}$.\n\nStep 2: Validation of the Problem.\nThe problem is scientifically grounded. It describes a key pathway in immunology—the activation of the NLRP3 inflammasome by the DAMP molecule ATP via the P2RX7 receptor—using the standard biochemical framework of receptor-ligand binding kinetics. The definitions of the dissociation constant and fractional occupancy are standard. The given numerical values for $K_{d}$ and ATP concentrations are biologically plausible for this system. The problem is well-posed, self-contained, and objective, with all necessary information provided for a unique solution. It is free from contradictions, ambiguities, and scientific inaccuracies.\n\nStep 3: Verdict and Action.\nThe problem is deemed valid. A solution will be provided.\n\nThe derivation of the fractional occupancy, $f$, begins with the provided definitions.\nThe equilibrium dissociation constant is:\n$$\nK_{d} = \\frac{[L][R]}{[RL]}\n$$\nThe conservation of total receptors is:\n$$\n[R]_{T} = [R] + [RL]\n$$\nThe fractional occupancy is:\n$$\nf = \\frac{[RL]}{[R]_{T}}\n$$\nWe seek to express $f$ as a function of the ligand concentration $[L]$ and the dissociation constant $K_{d}$. First, we rearrange the definition of $K_{d}$ to solve for the concentration of free receptor, $[R]$:\n$$\n[R] = \\frac{K_{d} [RL]}{[L]}\n$$\nNext, we substitute this expression for $[R]$ into the equation for total receptor concentration:\n$$\n[R]_{T} = \\frac{K_{d} [RL]}{[L]} + [RL]\n$$\nFactoring out the term for the ligand-bound receptor, $[RL]$, gives:\n$$\n[R]_{T} = [RL] \\left( \\frac{K_{d}}{[L]} + 1 \\right)\n$$\nTo find the fractional occupancy, $f$, we rearrange this equation to form the ratio $\\frac{[RL]}{[R]_{T}}$:\n$$\nf = \\frac{[RL]}{[R]_{T}} = \\frac{1}{\\frac{K_{d}}{[L]} + 1}\n$$\nMultiplying the numerator and denominator by $[L]$ yields the final expression, which is the Hill-Langmuir equation for a single, independent binding site:\n$$\nf = \\frac{[L]}{[L] + K_{d}}\n$$\nThis is the general expression for fractional occupancy.\n\nNow, we evaluate the fractional occupancy for the two specified ATP concentrations. It is necessary to use consistent units for concentration. We will use micromolar ($\\mu\\text{M}$).\nThe given dissociation constant is $K_{d} = 100\\,\\mu\\text{M}$.\n\nCase 1: Diffuse ATP field.\nThe ligand concentration is $[L]_{1} = 10\\,\\mu\\text{M}$.\nThe fractional occupancy, $f_{1}$, is:\n$$\nf_{1} = \\frac{[L]_{1}}{[L]_{1} + K_{d}} = \\frac{10\\,\\mu\\text{M}}{10\\,\\mu\\text{M} + 100\\,\\mu\\text{M}} = \\frac{10}{110} = \\frac{1}{11}\n$$\n\nCase 2: Peri-necrotic microdomain.\nThe ligand concentration is $[L]_{2} = 1\\,\\text{mM}$. We convert this to $\\mu\\text{M}$: $1\\,\\text{mM} = 1000\\,\\mu\\text{M}$.\nThe fractional occupancy, $f_{2}$, is:\n$$\nf_{2} = \\frac{[L]_{2}}{[L]_{2} + K_{d}} = \\frac{1000\\,\\mu\\text{M}}{1000\\,\\mu\\text{M} + 100\\,\\mu\\text{M}} = \\frac{1000}{1100} = \\frac{10}{11}\n$$\n\nThe problem assumes the likelihood of NLRP3 inflammasome activation scales proportionally with P2RX7 occupancy. Comparing the two occupancies, we find $f_{2} = \\frac{10}{11} \\approx 0.909$ and $f_{1} = \\frac{1}{11} \\approx 0.0909$. Since $f_{2} > f_{1}$, the peri-necrotic microdomain with an ATP concentration of $1\\,\\text{mM}$ is substantially more likely to trigger NLRP3 inflammasome activation than the diffuse field with an ATP concentration of $10\\,\\mu\\text{M}$.\n\nFinally, we calculate the fold-change in receptor occupancy, which is the ratio of $f_{2}$ to $f_{1}$:\n$$\n\\text{Fold-change} = \\frac{f_{2}}{f_{1}} = \\frac{\\frac{10}{11}}{\\frac{1}{11}} = 10\n$$\nThe problem requires this answer to be rounded to three significant figures. As an exact integer, $10$ must be written as $10.0$ to reflect this precision.", "answer": "$$\\boxed{10.0}$$", "id": "2858396"}, {"introduction": "Immunological phenomena are rarely driven by a single pathway; more often, they result from an interplay of multiple signals. A powerful experimental strategy to untangle this complexity is the use of specific inhibitors. This final practice places you in the role of an experimentalist analyzing data from an experiment that uses apyrase to specifically block ATP signaling. You will develop a mathematical model of the system to quantify the precise contribution of the ATP-P2RX7 axis to the overall inflammasome activation, measured by Interleukin-1β (IL-1β) secretion [@problem_id:2858414].", "problem": "A population of lipopolysaccharide-primed bone marrow–derived macrophages is exposed to supernatants from tumor cells undergoing immunogenic cell death. Interleukin-1β (IL-1β) secretion is quantified by Enzyme-Linked Immunosorbent Assay (ELISA) as an indicator of NOD-, LRR- and pyrin domain-containing protein 3 (NLRP3) inflammasome activation. Extracellular adenosine triphosphate (ATP) released by dying cells is a canonical damage-associated molecular pattern (DAMP) that activates purinergic P2X7 receptors to provide the inflammasome activation signal, while apyrase (an ATP-diphosphohydrolase) hydrolyzes ATP to adenosine monophosphate, thereby removing the ATP signal. Assume additivity of stimuli in the linear response regime: the IL-1β concentration measured by ELISA is the sum of a baseline term due to medium, an ATP-dependent term, and an ATP-independent DAMP term. In the presence of apyrase, only the ATP-dependent term is eliminated.\n\nAn ELISA kit yields a linear standard curve within the measured range that can be represented as\n$$ C = m \\left(A - A_{0}\\right), $$\nwhere $C$ is the IL-1β concentration in $\\mathrm{pg \\, mL^{-1}}$, $A$ is the measured absorbance at $450 \\, \\mathrm{nm}$, $A_{0}$ is the blank absorbance, and $m$ is the slope. For this assay, $m = 4000 \\, \\mathrm{pg \\, mL^{-1} \\, absorbance^{-1}}$ and $A_{0} = 0.060$.\n\nTriplicate absorbance readings are obtained for three conditions:\n- Medium control (no DAMPs): $A = 0.082, \\; 0.080, \\; 0.085$.\n- Dying-cell supernatant without apyrase: $A = 0.480, \\; 0.495, \\; 0.488$.\n- Dying-cell supernatant with apyrase: $A = 0.210, \\; 0.205, \\; 0.212$.\n\nUsing only the foundational assumptions stated above (Beer–Lambert linearity underlying the ELISA calibration, additivity of baseline and stimulus components in the linear regime, and apyrase eliminating only the ATP-dependent contribution), compute the decimal fraction that quantifies the degree to which ATP drives inflammasome activation, defined as the fraction of stimulus-specific IL-1β (above medium baseline) that is inhibited by apyrase. Express your final answer as a dimensionless decimal and round to four significant figures.", "solution": "The problem statement is parsed and validated. All givens are extracted:\n- ELISA calibration: $C = m(A - A_0)$, with slope $m = 4000 \\, \\mathrm{pg \\, mL^{-1} \\, absorbance^{-1}}$ and blank absorbance $A_0 = 0.060$.\n- Additivity assumption for IL-1β concentration ($C$): The total concentration is the sum of a baseline term ($C_{base}$), an ATP-dependent term ($C_{ATP}$), and an ATP-independent DAMP term ($C_{ATP-indep}$).\n- Apyrase assumption: Apyrase eliminates only the ATP-dependent term.\n- Absorbance data (triplicates):\n  - Medium control: $A_{med,1}=0.082, A_{med,2}=0.080, A_{med,3}=0.085$.\n  - Supernatant without apyrase: $A_{sup,1}=0.480, A_{sup,2}=0.495, A_{sup,3}=0.488$.\n  - Supernatant with apyrase: $A_{apy,1}=0.210, A_{apy,2}=0.205, A_{apy,3}=0.212$.\n\nThe problem is scientifically grounded, well-posed, and objective. It describes a standard immunobiological experiment and asks for a quantitative analysis based on a clear, simplified model. The data and assumptions are self-contained and consistent. The problem is valid.\n\nWe proceed to the solution. Let $\\bar{C}_{med}$, $\\bar{C}_{sup}$, and $\\bar{C}_{apy}$ be the mean IL-1β concentrations for the medium control, supernatant-treated, and supernatant-with-apyrase-treated conditions, respectively. According to the additivity principle stated in the problem:\n1. The medium control measures the baseline secretion:\n$$ \\bar{C}_{med} = C_{base} $$\n2. The supernatant without apyrase measures the total stimulus-induced secretion on top of the baseline:\n$$ \\bar{C}_{sup} = C_{base} + C_{ATP} + C_{ATP-indep} $$\n3. The supernatant with apyrase measures the secretion where the ATP-dependent component is eliminated:\n$$ \\bar{C}_{apy} = C_{base} + C_{ATP-indep} $$\n\nThe problem asks for the fraction of stimulus-specific IL-1β that is inhibited by apyrase. Let us define these quantities formally.\n- The total stimulus-specific IL-1β secretion is the increase in concentration above the medium baseline when cells are exposed to the supernatant.\n$$ C_{stimulus} = \\bar{C}_{sup} - \\bar{C}_{med} = (C_{base} + C_{ATP} + C_{ATP-indep}) - C_{base} = C_{ATP} + C_{ATP-indep} $$\n- The amount of IL-1β secretion inhibited by apyrase is the difference between the secretion without and with apyrase. This isolates the ATP-dependent contribution.\n$$ C_{inhibited} = \\bar{C}_{sup} - \\bar{C}_{apy} = (C_{base} + C_{ATP} + C_{ATP-indep}) - (C_{base} + C_{ATP-indep}) = C_{ATP} $$\nThe desired fraction, which we denote as $F_{ATP}$, is the ratio of the inhibited portion to the total stimulus-specific portion:\n$$ F_{ATP} = \\frac{C_{inhibited}}{C_{stimulus}} = \\frac{\\bar{C}_{sup} - \\bar{C}_{apy}}{\\bar{C}_{sup} - \\bar{C}_{med}} $$\nThe ELISA equation, $C = m(A - A_0)$, provides a linear relationship between concentration $C$ and absorbance $A$. We can substitute this into the expression for $F_{ATP}$. Let $\\bar{A}_{med}$, $\\bar{A}_{sup}$, and $\\bar{A}_{apy}$ be the mean absorbances for the three conditions.\n$$ F_{ATP} = \\frac{m(\\bar{A}_{sup} - A_0) - m(\\bar{A}_{apy} - A_0)}{m(\\bar{A}_{sup} - A_0) - m(\\bar{A}_{med} - A_0)} $$\nThe constants $m$ and $A_0$ can be factored out and cancelled:\n$$ F_{ATP} = \\frac{m(\\bar{A}_{sup} - \\bar{A}_{apy})}{m(\\bar{A}_{sup} - \\bar{A}_{med})} = \\frac{\\bar{A}_{sup} - \\bar{A}_{apy}}{\\bar{A}_{sup} - \\bar{A}_{med}} $$\nThis demonstrates that the fraction can be calculated directly from the absorbance values, without needing to compute the intermediate concentrations. This is a robust feature of ratiometric analysis in linear systems.\n\nFirst, we calculate the mean absorbance for each condition from the triplicate readings.\n- Medium control:\n$$ \\bar{A}_{med} = \\frac{0.082 + 0.080 + 0.085}{3} = \\frac{0.247}{3} $$\n- Supernatant without apyrase:\n$$ \\bar{A}_{sup} = \\frac{0.480 + 0.495 + 0.488}{3} = \\frac{1.463}{3} $$\n- Supernatant with apyrase:\n$$ \\bar{A}_{apy} = \\frac{0.210 + 0.205 + 0.212}{3} = \\frac{0.627}{3} = 0.209 $$\nNow, we substitute these mean values into the expression for $F_{ATP}$. The factor of $\\frac{1}{3}$ will cancel from the numerator and denominator, so we can use the sums of the absorbances directly.\n$$ F_{ATP} = \\frac{\\frac{1.463}{3} - \\frac{0.627}{3}}{\\frac{1.463}{3} - \\frac{0.247}{3}} = \\frac{1.463 - 0.627}{1.463 - 0.247} $$\nPerforming the subtractions:\n$$ F_{ATP} = \\frac{0.836}{1.216} $$\nFinally, we compute the decimal value of this fraction:\n$$ F_{ATP} \\approx 0.6875 $$\nThe problem requires the answer to be rounded to four significant figures. The calculated value $0.6875$ already has exactly four significant figures. Thus, no further rounding is necessary. This result indicates that extracellular ATP accounts for $68.75\\%$ of the inflammasome activation induced by the tumor cell supernatant under these experimental conditions.", "answer": "$$\n\\boxed{0.6875}\n$$", "id": "2858414"}]}